Submitting InstitutionUniversity of Cambridge
Unit of AssessmentPhilosophy
Summary Impact TypeSocietal
Research Subject Area(s)
Studies In Human Society: Policy and Administration
Law and Legal Studies: Law
Philosophy and Religious Studies: Philosophy
Summary of the impact
Tim Lewens' research into risk, trust and bioethics can be shown to have
informed and influenced policy debate. This work has shaped reports of the
Business Innovation and Skills working group on Science and Trust, and
also reports from the Nuffield Council on Bioethics. Lewens' key
contributions to the latter's Human Bodies Report have resulted in
invitations to give evidence to the Welsh National Assembly, thus helping
to shape the Assembly's drafting of its new bill on human transplantation.
His work on the Council's report on Mitochondrial Disorders has been
echoed in the Human Fertilisation and Embryology Authority's (HFEA's)
recent advice to UK Ministers, which aims to inform forthcoming debate to
alter existing legislation on experimental mitochondrial therapies.
Lewens' research has also led to his being asked to take on consulting
roles to industry, most recently with AstraZeneca.
Tim Lewens joined the department of History and Philosophy of Science
(HPS) at the University of Cambridge in 2000, initially as a Junior
Research Fellow. In 2002 he became a University Lecturer, was promoted to
Senior Lecturer in 2006, to Reader in 2010 and now to a Professorship in
the Department from this October. Since 2000 he has undertaken a series of
innovative studies of the concepts of risk, trust and their related roles
in discussions of bioethics and technology policy. Most of this work was
conducted by Lewens working alone, but some elements of the work have
involved substantial contributions from others. The most notable example
of this collaborative work was the co-authored report on The Universal
Ethical Code for Scientists and the `Crisis of Trust in Science' (2010),
which Tim Lewens wrote with Dr Stephen John, also of HPS. This piece of
novel research, which argued against the very idea of a generic crisis of
trust in science, and instead urged focus on more specific ways in which
scientific evidence is used within policy formation, was commissioned as
part of the government's Science in Society Programme review of `Science
and Trust' in 2009-10.
In broad terms, Lewens' work on risk (e.g. Lewens 2007a, 2008) aimed to
sketch a defensible version of the precautionary principle, and also to
clarify the ethical status of various forms of risk cost-benefit analysis.
His work in bioethics has assessed issues relating to modern
biotechnology, risk and identity (e.g. Lewens 2002, 2004, 2009, 2012). He
has criticised fashionable appeals to notions of human nature as they are
often applied to debates over the introduction of new and potentially
risky biotechnologies (Lewens 2012), arguing that biology grounds only
very permissive conceptions of human nature, which cannot be used to
justify conservative opposition to human enhancement. He has also been a
consistent opponent of `genetic exceptionalism', whereby genetic
technologies are singled out for specific forms of regulatory oversight or
ethical censure (e.g. Lewens 2002, 2004, 2009). In this work Lewens casts
doubt on the basic ethical justification for wholesale bans on
modifications to the `germ-line', for example, in a manner which has
consequences for the ethical permissibility of very new techniques for
modification of mitochondrial genomes. In all cases, Lewens' work is
grounded in appeals to work in modern biology, as well as to the broader
historical contexts of these debates. He has consistently aimed to link
this work to issues of political concern, as exemplified by his work on
altruism and the political use of images of human nature in his (2007b)
Darwin. This book distinguished various important notions of altruism, and
clarified their relationship to moral images of human nature.
References to the research
• Lewens, T. `Development Aid: On Ontogeny and Ethics' Studies in
History and Philosophy of Biological and Biomedical Sciences 23
(2002), 195-217. DOI: 10.1016/S0039-3681(02)00017-1
• Lewens, T `What is Genethics?' Journal of Medical Ethics 30
(2004), 326-328, DOI: 10.1136/jme.2002.002642.
• Lewens, T `Risk and Philosophy' in Lewens, T. (ed.) Risk:
Philosophical Perspectives. London: Routledge (2007a) 1-20.
Available on request.
• Lewens, T Darwin. London: Routledge (2007b). Available on
• Lewens, T `Taking Sensible Precautions' Lancet 371 (2008):
1992-1993, DOI: 10.1016/S0140-6736(08)60857-0.
• Lewens, T `Enhancement and Human Nature: The Case of Sandel' Journal
of Medical Ethics 35 (2009): 354-356, DOI: 10.1136/jme.2008.028423.
• Lewens, T `Human Nature: The Very Idea' Philosophy and Technology
25 (2012): 459-474, DOI 10.1007/s13347-012-0063-x.
Except for the commissioned piece of research co-authored with John,
these items have all undergone peer-review, and are published either by
internationally respected presses, or by highly respected international
Details of the impact
Lewens' research into risk, trust and bioethics has had broad impact
across government, industry and the policy sector more generally.
Lewens' work on risk and precaution (Lewens 2008) was cited in the
Nuffield Council on Bioethics' recent (2011) report on Human Bodies:
Donation for Treatment and Research [1, p. 146]. As a Council member, and
working party member, Lewens took a leading role in writing the report's
ethical framework for donation, and that framework drew in important ways
on his own background work on altruism (outlined in Lewens (2007b)). An
official at the Nuffield Council clarified Lewens' involvement as follows:
"The ethical framework in the Council's 2011 report Human Bodies: donation
for medicine and research derived substantially from the original ethical
analysis undertaken by Tim Lewens (a member both of the Working Party and
of the Council itself): in particular his detailed analysis of the
different claims associated with 'altruism', and his subsequent
categorisation of particular forms of encouragement to donate bodily
material as either 'altruist-focused' (interventions that act through
encouraging altruistic motivations) or 'non-altruist-focused'
(interventions that may act to encourage donation, regardless of whether
or not the potential donor may experience altruistic motivations). This
consideration of altruism was fundamental in shaping the Working Party's
consideration of the role of incentives in the context of donation. In the
additional contested area of consent for donation ('opt-in' vs. 'opt-out'
arguments for organ donation in particular), Tim's analysis of the
justifications offered for non-health opt-out schemes (such as those used
for occupational pensions) was vital in leading the working party to
conclude that the key ethical requirement in this area should be to ensure
that the taking of bodily materials after death should be based on the
clearest possible information as to the person's wishes." 
The report's recommendation for increasing payment to egg donors was
taken up by the Human Fertilisation and Embryology Authority (HFEA). 
Lewens' own involvement in working on the Human Bodies report, especially
with respect to its discussion of `opt-in' and `opt-out' consent schemes
for donation, resulted in an invitation to give oral evidence to the Welsh
National Assembly in January 2013, in connection with its new Human
Transplantation (Wales) Bill . His comments during the evidence session
on the need for clarity in communication associated with the proposed
changes to an `opt-out' system of consent, on the ethical defensibility of
a system of `presumed consent', and on the need to ensure suitable
donation of materials for research purposes were all translated into
recommendations in the National Assembly's Stage 1 Committee Report,
published in March 2013 . Lewens was named several times in this report
as the source for these recommendations. He was subsequently invited (in
April 2013) by the Human Tissue Authority (HTA)—the official regulatory
body responsible for overseeing uses of human tissues—to offer advice and
comment on its draft Code of Conduct applying to the new Welsh Legislation
. The Director of Strategy and Quality at the HTA has explained that
"Dr Lewens was keen to work with us and his input on stressing the
legislation was permissive rather than prescriptive, that Specialist
Nurses for Organ Donation do have discretion and this should be
highlighted and that there should be no inference that deemed consent was
a lesser form of consent, all added significantly to the second draft of
the document. Dr Lewens also suggested drafting amendments to change the
tone of the document, which were a great help and we believe make the
redraft more accessible. The draft document would not be either as well
drafted or well thought through without the input of Dr Lewens, and we are
grateful for his support." 
Lewens' work on trust, precaution, human nature and genetic enhancement
(Lewens 2004, Lewens 2009, Lewens and John 2010, Lewens 2012) has been
cited by two further Nuffield Council reports: one entitled Emerging
Biotechnologies (2012), another entitled Novel Techniques for the
Prevention of Mitochondrial DNA Disorders (2012) [7, pp. 54, 60, 61].
Again, Lewens was centrally involved in formulating the ethical arguments
relating to identity and germ-line interventions which underpinned the
Mitochondrial Disorders report . The Director of the Nuffield Council,
has stated that "The role that Tim Lewens played in the preparation and
drafting of this important report was particularly notable. His work in
developing the ethical considerations, and especially in addressing issues
around identity in relation to genetic therapies, formed a very
substantial part of the arguments that sit at the heart of the report. His
further contribution in applying these ethical discussions to the novel
case of potential treatments for mitochondrial disorders was also critical
to the success of this report" . Lewens presented results of that
report at a launch event in the Palace of Westminster (June 2012), and at
the Trilateral Meeting of the French, German and UK National Ethics
Committees (November 2012). The report has been discussed in a recent
(March 2013) Parliamentary Office of Science and Technology (POST) report
on Preventing Mitochondrial Disease . The Nuffield Council's
conclusions regarding the ethical permissibility of mitochondrial
donation, the recommendation that gamete donors need not be mandatorily
identifiable to children in this particular context, and the requirement
of follow-up studies, were all echoed in the (March 2013) advice to
Ministers from the HFEA . Both the HFEA advice and the Nuffield
Council Report aim to inform future parliamentary deliberations on whether
to make these novel mitochondrial techniques legal.
Lewens and John's 2010 commissioned report to the Department of Business,
Innovation and Skills titled The Universal Ethical Code for Scientists and
the `Crisis of Trust in Science' provided a definition of trust and an
analysis of the `crisis of trust' in science, that was discussed and
endorsed by the Science and Trust expert group in their final (March 2010)
report to the then-Science Minister Lord Drayson . The report's action
plan recommended numerous initiatives aimed at improving trust in science,
and in 2012 an assessment of progress towards these goals was published
More generally, Lewens' work on science and trust, and his earlier
articles on the ethics of bioethics, have led to invitations to consult to
large pharmaceutical companies. In 2008, for example, Lewens was invited
to overhaul AstraZeneca's (AZ's) global policy on bioethics and in 2010 he
was asked to advise AZ on the ethical standing of research involving the
use of foetal tissue. AZ's Director of Science Policy explains that `Dr
Lewens' report...has resulted in a change of perception and understanding
of the ethical and moral issues surrounding human foetal tissue usage
maintained by the relevant team [at AZ].'  AZ's Director of Science
Policy has relied on Lewens' report when the issue has been raised at
several policy meetings, the most recent of which took place in May 2013.
Sources to corroborate the impact
 Nuffield Council Report on Human Bodies. Published online:
 An email from Person 1 (Assistant Director, Nuffield Council
on Bioethics) (29th March 2012) confirms Dr Lewens'
contribution to the Human Bodies study.
 HFEA Chair's Letter (28th January 2012)
`Implementation of the Outcomes of the Donation Review' http://www.hfea.gov.uk/6966.html
 Transcript of Lewens' evidence given to Welsh Assembly.
 Welsh Assembly Human Transplantation (Wales) Bill, Stage One
 An email from Person 2 (20th May 2013), Director of
Strategy and Quality at the Human Tissue Authority (HTA) confirms Lewens'
contribution to the HTA's draft Code of Practice relating to the new Welsh
 Nuffield Council Report on Mitochondrial Disorders. Published
 A letter from Person 3 (Director, Nuffield Council on
Bioethics) (October 2012) confirms Lewens' involvement in the Mitochondrial
 POST Briefing Document on Mitochondrial Disorders. Published
 HFEA Advice to Ministers on Mitiochondrial Replacement.
 Science and Trust Expert Group: Report and Action Plan,
 Science and Trust action plan review, available at:
 An email from Person 4 (R & D Policy Strategy Leader,
AstraZeneca), received 24th June 2013, explaining Dr Lewens'
work on research using foetal tissue.